These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 23600760)

  • 1. Rituximab biosimilars.
    Vital EM; Kay J; Emery P
    Expert Opin Biol Ther; 2013 Jul; 13(7):1049-62. PubMed ID: 23600760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.
    Brown JR; Cymbalista F; Sharman J; Jacobs I; Nava-Parada P; Mato A
    Oncologist; 2018 Mar; 23(3):288-296. PubMed ID: 29212732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab biosimilars for lymphoma in Europe.
    Jurczak W; Długosz Danecka M; Buske C
    Expert Opin Biol Ther; 2019 Oct; 19(10):1045-1056. PubMed ID: 31512535
    [No Abstract]   [Full Text] [Related]  

  • 5. Biosimilars in oncology: from development to clinical practice.
    Rak Tkaczuk KH; Jacobs IA
    Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.
    Buske C; Ogura M; Kwon HC; Yoon SW
    Future Oncol; 2017 May; 13(15s):5-16. PubMed ID: 28482702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin.
    Ly S; Nedosekin D; Wong HK
    Am J Clin Dermatol; 2023 Mar; 24(2):247-273. PubMed ID: 36630066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars: Considerations for Oncology Nurses
.
    Vizgirda V; Jacobs I
    Clin J Oncol Nurs; 2017 Apr; 21(2):E54-E60. PubMed ID: 28315542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
    Cuellar S; McBride A; Medina P
    Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Launching biosimilar rituximab: an industry opinion on biosimilar uptake in Europe.
    Trollope R; Johnson S; Ireland H
    Immunotherapy; 2017 Jun; 9(7):527-529. PubMed ID: 28523951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
    Ogura M; Coiffier B; Kwon HC; Yoon SW
    Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
    Zelenetz AD; Ahmed I; Braud EL; Cross JD; Davenport-Ennis N; Dickinson BD; Goldberg SE; Gottlieb S; Johnson PE; Lyman GH; Markus R; Matulonis UA; Reinke D; Li EC; DeMartino J; Larsen JK; Hoffman JM
    J Natl Compr Canc Netw; 2011 Sep; 9 Suppl 4():S1-22. PubMed ID: 21976013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
    Moorkens E; Vulto AG; Huys I
    MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory and clinical considerations for biosimilar oncology drugs.
    Bennett CL; Chen B; Hermanson T; Wyatt MD; Schulz RM; Georgantopoulos P; Kessler S; Raisch DW; Qureshi ZP; Lu ZK; Love BL; Noxon V; Bobolts L; Armitage M; Bian J; Ray P; Ablin RJ; Hrushesky WJ; Macdougall IC; Sartor O; Armitage JO
    Lancet Oncol; 2014 Dec; 15(13):e594-e605. PubMed ID: 25456378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
    Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
    Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing clinical trials for biosimilars.
    Bui LA; Taylor C
    Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
    Declerck P; Danesi R; Petersel D; Jacobs I
    Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars 101: considerations for U.S. oncologists in clinical practice.
    Camacho LH; Frost CP; Abella E; Morrow PK; Whittaker S
    Cancer Med; 2014 Aug; 3(4):889-99. PubMed ID: 24810680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.